Streetbeat News

Products Services

RYTM

Rhythm Pharmaceuticals, Inc. (NASDAQ:RYTM) announced that a new International Classification of Diseases, Tenth Revision (ICD-10) diagnosis code for Bardet-Biedl Syndrome (BBS) was approved by the Centers for Disease Control and Prevention (CDC). The new code, Q87.83 Bardet-Biedl syndrome (BBS), takes effect Oct. 1, 2023.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 12:00 pm

ACB

Aurora Cannabis Inc. (NASDAQ:ACB) has announced a partnership with Brazilian company Herbarium to expand its hemp-derived CBD portfolio into Brazil. The company will launch its full-spectrum, single-source 3% CBD oil under the Herbarium brand, making it available to patients across Brazil under the direction of medical doctors.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:51 am

BRKR

DFLI

Dragonfly Energy has highlighted the use of Bruker Corporation's battery research equipment in its operations. The equipment is instrumental in Dragonfly's research and development efforts.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:47 am

BMR

Beamr Imaging Ltd (NASDAQ:BMR) has announced the second beta release of its cloud service for video optimization. The new release introduces APIs that allow customers to automate large-scale video optimization in the cloud.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:45 am

GOOG

GOOGL

MSFT

Alphabet Inc.'s Google is celebrating its 25th birthday this month. CEO Sundar Pichai reflected on the company's journey and the evolution of technology over the years. He emphasized the importance of Search, which remains at the core of Google's mission. Pichai also highlighted how Google has adapted to the fast-changing technology landscape, from the web to mobile internet and now AI. Google is testing out Bard in Search, a conversational chatbot with visual elements, despite competition from Microsoft Corp.'s OpenAI's ChatGPT.

Portfolio Pulse from Rounak Jain

September 06, 2023 | 11:44 am

ERNA

LCTX

Lineage Cell Therapeutics Inc (LCTX) has started development activities under its exclusive license agreement with Eterna Therapeutics Inc (ERNA) to generate a novel hypoimmune induced pluripotent stem cell (iPSC) line. This is part of a strategic collaboration announced in February 2023, where Eterna is developing engineered hypoimmune iPSC lines that Lineage will evaluate for differentiation into cell transplant product candidates for central nervous system diseases and other neurology indications. Lineage will make payments to Eterna in connection with Eterna’s successful development and delivery of certain materials.

Portfolio Pulse from Vandana Singh

September 06, 2023 | 11:40 am

ERNA

LCTX

Lineage Cell Therapeutics has announced that it is developing a hypoimmune pluripotent cell line for neurology indications under its partnership with Eterna Therapeutics.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:40 am

LMT

Lockheed Martin has updated its delivery forecast for 2023, now expecting to deliver 97 aircraft, all in TR-2 configuration. The company does not anticipate this to impact its 2023 financial outlook. The number of 2024 F-35 deliveries will depend on the delivery of the first TR-3 aircraft and the time needed for customer acceptance. The company is still assessing impacts to 2024.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:38 am

BBIO

The FDA and European Medicines Agency have indicated that a single, one-year, 2:1 randomized, placebo-controlled trial would be acceptable as a registrational study for BridgeBio Pharma's Infigratinib approval for children with Achondroplasia. The trial is expected to start by the end of 2023.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:36 am

LMT

Lockheed Martin has announced in a filing that it anticipates delivering the first TR-3 jet between April and June 2024.

Portfolio Pulse from Benzinga Newsdesk

September 06, 2023 | 11:36 am